IL23A and inflammatory bowel disease: Therefore, selective blocking of the IL-23 dependent Th17 differentiation pathway through the employment of the anti-inflammatory properties of probiotic strains, simultaneously restoring the eubiotic state of the gut microbiota ecosystem, remains an attractive therapeutic strategy in IBD [35].